scPharmaceuticals (SCPH)
(Delayed Data from NSDQ)
$4.60 USD
+0.48 (11.65%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $4.60 0.00 (0.00%) 6:22 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SCPH 4.60 +0.48(11.65%)
Will SCPH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SCPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SCPH
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
SCPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates
scPharmaceuticals, Inc. (SCPH) Loses -21.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for SCPH
Biotech Alert: Searches spiking for these stocks today
scPharmaceuticals (SCPH) Receives a Buy from Craig-Hallum
These 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts
Commit To Purchase scPharmaceuticals At $2.50, Earn 14.4% Annualized Using Options
scPharmaceuticals to Present at the Jefferies Global Healthcare Conference